Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, imlifidase, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Renal and urinary disorders, PIP number:

Submitted by Anonymous (not verified) on 3 July 2026 - 9:08

Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, imlifidase, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Renal and urinary disorders, PIP number: EMEA-002183-PIP03-23

Human medicines European public assessment report (EPAR): NeoRecormon, epoetin beta, Date of authorisation: 16/07/1997, Revision: 35, Status: Authorised

Submitted by Anonymous (not verified) on 3 July 2026 - 9:07

Human medicines European public assessment report (EPAR): NeoRecormon, epoetin beta, Date of authorisation: 16/07/1997, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, Date of authorisation: 23/04/2007, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 3 July 2026 - 8:52

Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, Date of authorisation: 23/04/2007, Revision: 29, Status: Authorised

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 June 2026, 12:30 (CEST) to 17 June 2026, 17:30 (CEST)

Submitted by Anonymous (not verified) on 3 July 2026 - 8:44

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 June 2026, 12:30 (CEST) to 17 June 2026, 17:30 (CEST)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More